517 related articles for article (PubMed ID: 35569466)
1. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
[TBL] [Abstract][Full Text] [Related]
2. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
3. Salvage Whole-Pelvic Radiation and Long-Term Androgen-Deprivation Therapy in the Management of High-Risk Prostate Cancer: Long-Term Update of the McGill 0913 Study.
Elakshar S; Tolba M; Tisseverasinghe S; Pruneau L; Di Lalla V; Bahoric B; Niazi T
Curr Oncol; 2023 Aug; 30(8):7252-7262. PubMed ID: 37623007
[TBL] [Abstract][Full Text] [Related]
4. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Carrie C; Magné N; Burban-Provost P; Sargos P; Latorzeff I; Lagrange JL; Supiot S; Belkacemi Y; Peiffert D; Allouache N; Dubray BM; Servagi-Vernat S; Suchaud JP; Crehange G; Guerif S; Brihoum M; Barbier N; Graff-Cailleaud P; Ruffion A; Dussart S; Ferlay C; Chabaud S
Lancet Oncol; 2019 Dec; 20(12):1740-1749. PubMed ID: 31629656
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
Kneebone A; Fraser-Browne C; Duchesne GM; Fisher R; Frydenberg M; Herschtal A; Williams SG; Brown C; Delprado W; Haworth A; Joseph DJ; Martin JM; Matthews JHL; Millar JL; Sidhom M; Spry N; Tang CI; Turner S; Wiltshire KL; Woo HH; Davis ID; Lim TS; Pearse M
Lancet Oncol; 2020 Oct; 21(10):1331-1340. PubMed ID: 33002437
[TBL] [Abstract][Full Text] [Related]
7. Combined Long-Term Androgen Deprivation and Pelvic Radiotherapy in the Post-operative Management of Pathologically Defined High-Risk Prostate Cancer Patients: Results of the Prospective Phase II McGill 0913 Study.
Kucharczyk MJ; Tsui JMG; Khosrow-Khavar F; Bahoric B; Souhami L; Anidjar M; Probst S; Chaddad A; Sargos P; Niazi T
Front Oncol; 2020; 10():312. PubMed ID: 32226774
[No Abstract] [Full Text] [Related]
8. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
Sargos P; Chabaud S; Latorzeff I; Magné N; Benyoucef A; Supiot S; Pasquier D; Abdiche MS; Gilliot O; Graff-Cailleaud P; Silva M; Bergerot P; Baumann P; Belkacemi Y; Azria D; Brihoum M; Soulié M; Richaud P
Lancet Oncol; 2020 Oct; 21(10):1341-1352. PubMed ID: 33002438
[TBL] [Abstract][Full Text] [Related]
9. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.
Ramey SJ; Agrawal S; Abramowitz MC; Moghanaki D; Pisansky TM; Efstathiou JA; Michalski JM; Spratt DE; Hearn JWD; Koontz BF; Liauw SL; Pollack A; Anscher MS; Den RB; Stephans KL; Zietman AL; Lee WR; Stephenson AJ; Tendulkar RD
Eur Urol; 2018 Jul; 74(1):99-106. PubMed ID: 29128208
[TBL] [Abstract][Full Text] [Related]
10. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
11. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
Roach M; Moughan J; Lawton CAF; Dicker AP; Zeitzer KL; Gore EM; Kwok Y; Seider MJ; Hsu IC; Hartford AC; Horwitz EM; Yamoah K; Jones CU; Michalski JM; Lee WR; Pisansky TM; Rabinovitch R; Rotman M; Pryzant RM; Kim HE; Thomas CR; Shipley WU; Sandler HM
Lancet Oncol; 2018 Nov; 19(11):1504-1515. PubMed ID: 30316827
[TBL] [Abstract][Full Text] [Related]
12. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
13. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
[TBL] [Abstract][Full Text] [Related]
14. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial.
Jones CU; Pugh SL; Sandler HM; Chetner MP; Amin MB; Bruner DW; Zietman AL; Den RB; Leibenhaut MH; Longo JM; Bahary JP; Rosenthal SA; Souhami L; Michalski JM; Hartford AC; Amin PP; Roach M; Yee D; Efstathiou JA; Rodgers JP; Feng FY; Shipley WU
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):294-303. PubMed ID: 34481017
[TBL] [Abstract][Full Text] [Related]
15. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial.
Zapatero A; Guerrero A; Maldonado X; Álvarez A; San-Segundo CG; Rodríguez MÁC; Solé JM; Olivé AP; Casas F; Boladeras A; de Vidales CM; de la Torre MLV; Vara S; Sanz JL; Calvo FA
Lancet Oncol; 2022 May; 23(5):671-681. PubMed ID: 35427469
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
Hurwitz MD; Harris J; Sartor O; Xiao Y; Shayegan B; Sperduto PW; Badiozamani KR; Lawton CAF; Horwitz EM; Michalski JM; Roof K; Beyer DC; Zhang Q; Sandler HM
Cancer; 2017 Jul; 123(13):2489-2496. PubMed ID: 28323339
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy and short-term androgen deprivation for localized prostate cancer.
Jones CU; Hunt D; McGowan DG; Amin MB; Chetner MP; Bruner DW; Leibenhaut MH; Husain SM; Rotman M; Souhami L; Sandler HM; Shipley WU
N Engl J Med; 2011 Jul; 365(2):107-18. PubMed ID: 21751904
[TBL] [Abstract][Full Text] [Related]
20. First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy.
Valicenti RK; Pugh SL; Trabulsi EJ; Sartor O; Ko EC; Girvigian MR; Rosenthal SA; Shaves ME; Hoffman-Censits JH; Schallenkamp J; Sandler HM
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):695-701. PubMed ID: 29413282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
